Tysabri

News

Sandoz launches first biosimilar Tysabri in US

Biogen is facing biosimilar competition to its multiple sclerosis therapy Tysabri in the US for the first time, as Sandoz enters the market.

News

Polpharma Bio gets first EU okay for Tysabri biosimilar

Polpharma Biologics has said it is the first company to get approval in the EU for a biosimilar version of Biogen’s blockbuster multiple sclerosis therapy Tysabri.

News

First Tysabri biosimilar cleared by FDA for MS

Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overc

News

Whistleblower gets $250m as Biogen settles US kickbacks case

Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs.

News

Novartis takes aim at MS blockbuster Tysabri in US and Europ...

Regulators in the US and Europe have started to review Novartis' biosimilar version of Biogen's big-selling multiple sclerosis therapy Tysabri, which could reach the market next year.

News

Polpharma in pole position for biosimilar Tysabri in Europe

Polpharma Biologics has become the first company to file for approval in the EU of a biosimilar version of Biogen's blockbuster multiple sclerosis therapy

Sandoz launches first biosimilar Tysabri in US

Polpharma Bio gets first EU okay for Tysabri biosimilar

First Tysabri biosimilar cleared by FDA for MS

Whistleblower gets $250m as Biogen settles US kickbacks case

Novartis takes aim at MS blockbuster Tysabri in US and Europ...

Polpharma in pole position for biosimilar Tysabri in Europe

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Tysabri

Editor's Picks